

## CONTENTS

---

<i>Preface</i> .....	(v)
<i>Contributors</i> .....	(vii)

### Chapter – 1

#### **Iontophoretic Drug Delivery**

1.1 Introduction .....	1
1.2 Components of Normal Human Skin .....	2
1.3 Problems with the Transdermal Route for Drug Delivery .....	4
1.4 Drug in the Delivery Device.....	4
1.5 Iontophoresis .....	6
1.6 Selection Criteria for Drug Candidates .....	8
1.7 Principle and Basic Device.....	8
1.8 Factors Affecting Iontophoretic Delivery .....	9
1.8.1 Physiochemical Factors Affecting Iontophoresis .....	10
1.8.1.1 pH of the Drug Solution.....	10
1.8.1.2 Size and Salt.....	11
1.8.1.3 Ion Competition for Iontophoretic Transport .....	11
1.8.2 Formulation Factors Affecting Iontophoresis.....	12
1.8.2.1 Current Strength and Types .....	12
1.8.2.2 Electrode Types.....	12
1.8.3 Biological Factors.....	13
1.9 Mechanism of Iontophoresis .....	14
1.10 Applications of Iontophoresis .....	14
1.10.1 Topical Delivery .....	14
1.10.2 Treatment of Hyperhydrosis.....	15
1.10.3 Diagnostic Applications. ....	15
1.10.4 Otorhinolaryngology .....	15
1.10.5 Dentistry .....	15
1.11 Case Study .....	16
1.11.1 Rational for Drug Selection.....	16
1.11.2 Materials and Methods .....	17
1.11.2.1 Preparation of Rat Abdominal Skin .....	17
1.11.2.2 Preparation of Electrodes .....	17

**(xii) Contents**

---

1.11.2.3 Iontophoresis of LSP .....	17
1.11.2.4 HPLC Analysis of LSP .....	18
1.11.2.5 Experimental Design .....	18
1.11.3 Results and Discussion .....	19
1.11.3.1 Data Analysis .....	20
1.11.3.2 Optimization .....	21
1.12 Conclusion .....	21
References .....	21

**Chapter – 2**

**Solid Lipid Nanoparticles**

2.1 Introduction .....	27
2.2 Solid Lipid Nanoparticles .....	29
2.3 Advantages of Solid Lipid Nanoparticles .....	30
2.4 Choice of Drug Candidates for SLNs .....	31
2.5 Enhancement in Oral Absorption .....	32
2.5.1 Dissolution/Solubilization .....	32
2.5.2 Stimulation of Lymphatic Transport .....	33
2.5.3 Gastric Residence Time .....	33
2.5.4 Affecting Intestinal Permeability .....	33
2.5.5 Reduced Metabolism and Efflux Activity .....	33
2.5.6 Prevent First Pass Metabolism .....	33
2.6 Factors to be Considered in the Formulation of Solid Lipid Nanoparticles .....	34
2.6.1 Excipients used in the Formulation of SLNs .....	34
2.6.2 Selection of Lipids .....	35
2.6.3 Selection of Emulsifier .....	35
2.6.4 Selection of Co-Emulsifier .....	36
2.6.5 Drug Lipid Solubility .....	36
2.7 Lipids and Emulsifiers for Solid Lipid Nanoparticles .....	36
2.8 Uptake of Solid Lipid Nanoparticles .....	38
2.8.1 Mechanisms of also Increase the Degradation Rate of the Drug and the Carrier .....	40
2.8.2 Chylomicron Formation .....	40
2.9 Preparation of Solid Lipid Nanoparticles .....	41
2.9.1 High Shear Homogenization or Ultrasonication .....	42
2.9.2 Hot Homogenization .....	43

---

2.9.3	Cold Homogenization.....	45
2.9.4	Microemulsion based SLN Preparations .....	46
2.9.5	SLN Prepared by Solvent Emulsification/ Evaporation.....	47
2.9.6	W/O/W Double Emulsion Method .....	48
2.9.7	Solvent Injection Method .....	48
2.9.8	SLN Preparation by using Supercritical Fluid.....	49
2.9.9	Spray Drying Method .....	49
2.10	Comparison of Different Formulation Procedures .....	49
2.11	Drug Incorporation Models and Types of SLN/NLC.....	52
2.11.1	Drug Incorporation Models of SLN are.....	52
2.11.2	Drug Incorporation Models of NLC are .....	53
2.12	Lipophile Loading and Release in Lipid Nanoparticles .....	55
2.13	Secondary Steps for Preparation of Solid Lipid Nanoparticles.....	58
2.13.1	Solid Lipid Nanoparticle Stability .....	58
2.13.2	Sterilization.....	58
2.13.3	Lyophilization.....	59
2.13.4	Spray Drying .....	61
2.14	Characterization of Solid Lipid Nanoparticles .....	61
2.14.1	Particle Size and Zeta Potential .....	62
2.14.2	Degree of Lipid Crystallinity and Lipid Modification ..	63
2.14.3	Co-Existence of Additional Colloidal Structures and Dynamic Phenomena.....	64
2.14.4	Measurement of Entrapment Efficiency (EE %).....	65
2.14.5	<i>In vitro</i> and <i>Ex vivo</i> Methods for the Assessment of Drug Release from SLNs.....	65
2.14.5.1	Dialysis Tubing .....	65
2.14.5.2	Reverse Dialysis.....	66
2.14.5.3	Franz Diffusion Cell.....	66
2.14.6	<i>Ex vivo</i> Model for Determining Permeability across the Gut .....	66
2.15	Solid Lipid Nanoparticles Stability .....	67
2.15.1	Storage Stability .....	67
2.1.6	Applications of Solid Lipid Nanoparticles .....	67
2.16.1	Oral Delivery .....	67
2.16.2	Parenteral Delivery .....	68

**(xiv) Contents**

---

2.16.3	Vaccine Adjuvant .....	69
2.16.4	Transfection Agent .....	69
2.16.5	Topical Delivery .....	70
2.16.6	Solid Lipid Nanoparticles in Cancer Chemotherapy .....	70
2.16.7	Solid Lipid Nanoparticles for Delivering Peptides and Proteins.....	70
2.16.8	Solid Lipid Nanoparticles for Targeted Brain Drug Delivery .....	71
2.16.9	Solid Lipid Nanoparticles for Parasitic Diseases.....	71
2.16.10	Solid Lipid Nanoparticles for Ultrasonic Drug and Gene Delivery .....	72
2.16.11	SLN Applications for Improved Delivery of Antiretroviral Drugs to the Brain.....	72
2.16.12	SLN Applied to the Treatment of Malaria.....	73
2.16.13	Targeted Delivery of Solid Lipid Nanoparticles for the Treatment of Lung Diseases .....	73
2.16.14	Solid Lipid Nanoparticles for Lymphatic Targeting .....	74
2.16.15	Controlled Release of Perfumes and Repellents.....	74
2.16.16	SLNs for Potential Agriculture Application .....	74
2.16.17	Ocular Administration .....	74
2.17	Summary and Outlook.....	75
2.18	Case Study.....	76
2.18.1	Rational for Drug Selection.....	76
2.18.2	Materials and Methods .....	76
2.18.2.1	Partitioning Behavior of Rolaxifene in Various Triglyceride Lipids .....	76
2.18.2.2	Preparation of Raloxifene (RLX) Solidlipid Nanoparticles by Hot Homogenization Technique .....	76
2.18.2.3	Measurement of Size and Zeta Potential of SLN.....	77
2.18.2.4	Stability Studies .....	77
2.18.2.5	Effect of Freeze Drying.....	77
2.18.2.6	Characterization by Differential Scanning Calorimetry.....	77
2.18.2.7	HPLC Analysis of Raloxifene.....	78
2.18.2.8	Determination of Drug Content and Entrapment Efficiency .....	78

2.18.2.9	Entrapment Efficiency .....	78
2.18.2.10	Powder X-ray Diffractometry (PXRD) .....	78
2.18.2.11	<i>In vitro</i> Release Kinetics of Raloxifene from SLNs .....	78
2.18.3	Results and Discussions.....	79
2.18.3.1	Partitioning Behavior of Raloxifene .....	79
2.18.3.2	Preparation of SLN .....	79
2.18.3.3	Measurement of Size and Zeta Potential.....	79
2.18.3.4	Assay and Entrapment Efficiency .....	80
2.18.3.5	Effect of Freeze Drying.....	80
2.18.3.6	Differential Scanning Calorimetry .....	80
2.18.3.7	Powder X-ray Diffractometry (PXRD) .....	80
2.18.3.8	<i>In vitro</i> Release Kinetics of Raloxifene from SLN.....	81
2.18.3.9	Effect of pH of Dialysis Media on <i>In vitro</i> Release of Raloxifene.....	82
2.19	Conclusions .....	83
References	.....	84

### **Chapter – 3**

#### **Orodispersible Films**

3.1	Introduction .....	95
3.1.1	Oral Drug Delivery.....	95
3.1.2	Classification of Oral Films.....	101
3.1.3	Special Features and Advantages .....	101
3.1.4	Disadvantages.....	102
3.2	Oral Strip Formulation Components .....	102
3.2.1	Active Pharmaceutical Ingredient .....	103
3.2.2	Strip Forming Polymers.....	103
3.2.3	Plasticizers .....	104
3.2.4	Sweetening Agents .....	105
3.2.5	Saliva Stimulating Agent.....	106
3.2.6	Flavoring Agents .....	106
3.2.7	Coloring Agents.....	107
3.2.8	Stabilizing and Thickening Agents.....	107
3.3	Manufacturing Process of ODF .....	107
3.4	Technologies for ODF <sup>29</sup> .....	110
3.5	<i>In Vitro</i> Studies of ODF <sup>5</sup> .....	112
3.6	Conclusion.....	119
References	.....	130

## Chapter – 4

### Preformulation

4.1	Introduction .....	133
4.1.1	Goals of Preformulation .....	133
4.1.2	Major Constraints in Preformulation .....	134
4.1.3	Preformulation & Drug Design .....	134
4.2	Drug Substance and Physico-chemical Properties .....	135
4.2.1	Molecular Structure and Weight .....	135
4.2.2	Organoleptic Properties .....	135
4.2.3	Purity .....	136
4.2.4	Melting Point .....	137
4.2.5	Optical Activity .....	137
4.2.6	Particle Size .....	138
4.2.7	Physical Form .....	141
4.2.8	Density .....	144
4.2.9	Wetting .....	147
4.2.10	Solubility .....	150
4.2.11	Acid Dissociation Constant (pKa) .....	154
4.2.12	Dissolution .....	156
4.2.13	Partition Coefficient .....	161
4.2.14	Absorption Predictions .....	163
4.2.15	Hygroscopicity .....	165
4.2.16	Stability .....	166
4.2.17	Packaging Components .....	174
4.3	BCS as a Tool to Select Formulation Options .....	175
4.4	Conclusion .....	176
	References .....	193

## Chapter – 5

### Colon Targeting

5.1	Introduction .....	196
5.1.1	Absorption of Drugs in the Colon .....	199
5.1.2	Anatomy and Physiology of Colon .....	200
5.1.3	Factors to be Considered in the Design of Colon Specific Drug Delivery System .....	201
5.1.4	Colonic Diseases <sup>5,6</sup> .....	205

## Contents (xvii)

---

5.2 Drug Candidates for Colonic Drug Delivery.....	208
5.2.1 Colonic Absorption Barriers .....	210
5.3 Methods for Studying Colonic Drug Absorption .....	211
5.3.1 <i>In Vitro</i> Approaches .....	211
5.3.2 <i>In Vivo</i> Methods .....	212
5.4 Various Pharmaceutical Approaches to Colon Targeted Drug Delivery Systems.....	214
5.4.1 Covalent Linkage of the Drug with a Carrier .....	215
5.4.2 Approaches to Deliver the Intact Molecule to the Colon .....	220
5.5 Conclusion.....	227
References.....	243

### Chapter – 6

#### Hydrogels

6.1 Introduction .....	248
6.1.1 Classification and Basic Structure .....	249
6.2 Hydrogels in Drug Delivery .....	252
6.3 Improving the Delivery of Hydrogels .....	264
6.4 Novel Engineering of Hydrogels for Drug Delivery .....	273
6.5 Characterization of Hydrogels .....	276
6.6 Preparation of Hydrogels.....	283
6.7 Pharmaceutical Applications of Hydrogels .....	286
6.8 Conclusion.....	290
References.....	290

### Chapter – 7

#### Nanomedicines in Healthcare Systems

7.1 Introduction .....	307
7.1.1 Nanomedicine Technologies .....	311
7.1.2 Nanomedical Devices .....	311
7.1.3 Nanostructured Materials .....	314
7.2 Medical Nanorobotics of Tomorrow .....	325
7.2.1 Properties of Nanorobots.....	327
7.3 Application of Nanomedicines/Medical Devices.....	328
7.4 Conclusion.....	330
References.....	331

## Chapter – 8

### Brain Targeting

8.1 Introduction .....	335
8.2 Strategies for Brain Drug Delivery.....	340
8.2.1 Invasive Techniques .....	340
8.2.2 Non-Invasive Techniques .....	343
8.2.3 Miscellaneous Techniques.....	362
8.3 Pharmacokinetic Approaches .....	365
8.4 Patents Pertaining to CNS Drug Delivery .....	367
8.5 Computational Approach .....	370
8.6 Novel Approach for Brain Drug Delivery.....	372
8.7 Conclusion.....	375
References.....	391

## Chapter – 9

### Liposomes

9.1 Introduction .....	412
9.2 Classification and Structural Properties of Liposomes <sup>(2)</sup> .....	419
9.3 Liposomes Preparation/Production Methods <sup>2,12</sup> .....	422
9.4 Industrial Production of Liposomes .....	429
9.5 Factors Influencing Microencapsulation of Drugs in Liposomes <sup>2</sup> .....	434
9.6 Quality Control Assays for Liposomes <sup>1,28</sup> .....	437
9.7 Chemical Characterization of Liposomes .....	444
9.8 Different Classes of Liposomes.....	445
9.9 Various Routes of Liposomal Application .....	465
References.....	480

## Chapter – 10

### Osmotic Drug Delivery Systems

10.1 Introduction .....	491
10.2 Classification of Osmotic Drug Delivery Systems.....	493
10.2.1 Implantable Osmotic Drug Delivery Systems .....	494
10.2.2 Oral Osmotic Drug Delivery Systems .....	496

***Contents (xvix)***

---

10.2.3 Multilayer-Core Osmotic Systems/Multi Chamber System.....	500
10.2.4 Capsule-Based Osmotic Systems .....	501
10.3 Formulation Aspects.....	506
10.4 Conclusion.....	516
References .....	529
<b><i>Index</i></b> .....	<b>531</b>

